Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV
AM Lambeir, C Durinx, S Scharpé… - Critical reviews in …, 2003 - Taylor & Francis
Dipeptidyl-peptidase IV/CD26 (DPP IV) is a cell-surface protease belonging to the
prolyloligopeptidase family. It selectively removes the N-terminal dipeptide from peptides …
prolyloligopeptidase family. It selectively removes the N-terminal dipeptide from peptides …
Enhancing incretin action for the treatment of type 2 diabetes
DJ Drucker - Diabetes care, 2003 - Am Diabetes Assoc
OBJECTIVE—To examine the mechanisms of action, therapeutic potential, and challenges
inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the …
inherent in the use of incretin peptides and dipeptidyl peptidase-IV (DPP-IV) inhibitors for the …
Glucagon-like peptide-1 receptor signaling modulates β cell apoptosis
Glucagon-like peptide-1 (GLP-1) stimulates insulin secretion and augments β cell mass via
activation of β cell proliferation and islet neogenesis. We examined whether GLP-1 receptor …
activation of β cell proliferation and islet neogenesis. We examined whether GLP-1 receptor …
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 …
JJ Meier, B Gallwitz, S Salmen, O Goetze… - The journal of …, 2003 - academic.oup.com
The effects of different iv doses of glucagon-like peptide 1 (GLP-1) on glucose homeostasis
and gastric emptying were compared in patients with type 2 diabetes. Twelve patients with …
and gastric emptying were compared in patients with type 2 diabetes. Twelve patients with …
Suppression of glucose production by GLP-1 independent of islet hormones: a novel extrapancreatic effect
RL Prigeon, S Quddusi, B Paty… - American Journal of …, 2003 - journals.physiology.org
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that stimulates insulin secretion
and decreases glucagon release. It has been hypothesized that GLP-1 also reduces …
and decreases glucagon release. It has been hypothesized that GLP-1 also reduces …
Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes
DJ Drucker - Expert opinion on investigational drugs, 2003 - Taylor & Francis
Incretins are peptide hormones, exemplified by glucose-dependent insulinotropic peptide
and glucagon-like peptide 1 that are released from the gut in response to nutrient ingestion …
and glucagon-like peptide 1 that are released from the gut in response to nutrient ingestion …
Effects of GLP-1-(7–36)NH2, GLP-1-(7–37), and GLP-1- (9–36)NH2 on Intravenous Glucose Tolerance and Glucose-Induced Insulin Secretion in Healthy Humans
TP Vahl, BW Paty, BD Fuller, RL Prigeon… - The Journal of …, 2003 - academic.oup.com
Glucagon-like peptide 1 (GLP-1) is an insulin secretagogue synthesized in the intestine and
released in response to meal ingestion. It is secreted primarily in two forms, GLP-1-(7–37) …
released in response to meal ingestion. It is secreted primarily in two forms, GLP-1-(7–37) …
Effects of the novel (Pro3)GIP antagonist and exendin(9–39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic …
VA Gault, FPM O'harte, P Harriott, MH Mooney… - Diabetologia, 2003 - Springer
Aims/hypothesis This study examined the biological effects of the GIP receptor
antagonist,(Pro 3) GIP and the GLP-1 receptor antagonist, exendin (9–39) amide. Methods …
antagonist,(Pro 3) GIP and the GLP-1 receptor antagonist, exendin (9–39) amide. Methods …
Effectors of dipeptidyl peptidase IV
HU Demuth, K Glund, D Schlenzig, S Kruber - US Patent 6,548,481, 2003 - Google Patents
Dipeptide compounds and compounds analogous to dipep tide compounds that are formed
from an amino acid and a thiaZolidine or pyrrolidine group, and salts thereof used in the …
from an amino acid and a thiaZolidine or pyrrolidine group, and salts thereof used in the …
The glucagon-like peptides: a double-edged therapeutic sword?
TA Perry, NH Greig - Trends in pharmacological sciences, 2003 - cell.com
Abstract Glucagon-like peptide-1 (7–36)-amide (GLP-1) is an endogenous peptide that is
secreted from the gut in response to the presence of food. Recent studies have established …
secreted from the gut in response to the presence of food. Recent studies have established …